<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03218995</url>
  </required_header>
  <id_info>
    <org_study_id>4658-102</org_study_id>
    <nct_id>NCT03218995</nct_id>
  </id_info>
  <brief_title>Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 Skipping</brief_title>
  <official_title>An Open-label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, dose-escalation study to evaluate the safety,
      tolerability, PK, and efficacy of once-weekly IV infusions of eteplirsen in approximately 12
      male patients, ages 6 months to 48 months (inclusive), who have genotypically confirmed DMD
      with a deletion mutation amenable to exon 51 skipping.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 96 Weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal changes from baseline or clinically significant worsening of clinical safety laboratory abnormalities (hematology, chemistry, coagulation, and urinalysis)</measure>
    <time_frame>Change from Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal changes from baseline or worsening of vital signs</measure>
    <time_frame>Change from Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal changes from baseline or worsening of physical examination findings</measure>
    <time_frame>Change from Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal changes from baseline or clinically significant worsening of electrocardiogram (ECG) and echocardiogram (ECHO)</measure>
    <time_frame>Change from Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Cmax (Tmax)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t½)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of drug eliminated in urine (Ae%)</measure>
    <time_frame>24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Experimental: Treated Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eteplirsen</intervention_name>
    <description>Eteplirsen will be administered once a week by IV infusion for up to 96 weeks.
The starting dose is 2 mg/kg eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg over the course of the dose-titration period.</description>
    <arm_group_label>Experimental: Treated Group</arm_group_label>
    <other_name>AVI-4658</other_name>
    <other_name>EXONDYS 51®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male between 6 months to 48 months of age (inclusive)

          -  Diagnosis of DMD with a deletion mutation amenable to exon 51 skipping

          -  Parent(s) or legal guardian(s) who is willing to provide written informed consent

        Exclusion Criteria:

          -  Received treatment that might have an effect on muscle strength or function within 12
             weeks prior to dosing

          -  Received previous or current treatment with any experimental treatment

          -  Clinically significant illness other than DMD

          -  Clinically significant laboratory abnormality

          -  Any other condition that could interfere with the patient's participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>48 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Stehman-Breen</last_name>
    <role>Study Chair</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617.274.4000</phone>
    <email>medinfo@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke De Vos</last_name>
      <phone>+32 93321954</phone>
      <email>Elke.DeVos@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Nicolas Deconinck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Armand-Trousseau Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Duchene</last_name>
      <phone>+33 0171738313</phone>
      <email>d.duchene@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>François Renard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Wider</last_name>
      <phone>+49 76127043440</phone>
      <email>sabine.wider@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Janbernd Kirschner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Vizzino</last_name>
      <phone>+39 0630156330</phone>
      <email>Npi.clinicaltrials@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Eugenio M Mercuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Great Ormond Street Institute of Child Health</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manju Agarwal</last_name>
      <phone>+44 79052758</phone>
      <email>m.agarwal@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francesco Muntoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD</keyword>
  <keyword>Duchenne</keyword>
  <keyword>Eteplirsen</keyword>
  <keyword>dystrophy</keyword>
  <keyword>dystrophin</keyword>
  <keyword>exon 51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

